Purpose. Coronavirus disease 2019 (COVID-19) has been associated with a high rate of mortality and morbidity. While a high portion of COVID-19 patients have mild symptoms, a limited number of clinical trials have evaluated the clinical course of this large group of patients. This study was designed to investigate the demographics and clinical characteristics and comorbidity of nonhospitalized COVID-19 patients. Methods. This prospective, observational cohort study was performed on nonhospitalized adult patients (≥18 years) with COVID-19. Pharmacotherapy service was responsible for patients’ assessment for up to 1 month. Demographic characteristics, the onset of symptoms, severity, duration, laboratory data, and hospitalization rate were evaluated by a pharmacist-based monitoring program. Results. From 323 patients who had been referred to the emergency department, 105 individuals were recruited between April 26 and August 2, 2020. Most of the patients were female (66.7%) with a mean age of 39.39 years (SD: ± 15.82). The mean time of the symptom onset was 5.6 days (SD: ±1.79). The majority of patients suffered from fatigue (78.1%), sore throat (67.6%), cough (60%), and myalgia (55.2%). C-reactive protein, white blood cell, lymphocyte, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and hemoglobin levels were recovered significantly during the first two weeks (). Hydroxychloroquine, naproxen, diphenhydramine, azithromycin, and vitamin D3 were the most common medications administered (98%, 96%, 94%, 68%, and 57%, respectively). Forty patients were not symptom-free after the one-month follow-up, and 8 patients (7.6%) were required to revisit without the need for hospitalization. Anosmia (18.1%) and fatigue (17.1%) were the most common persisted symptoms. There were no significant differences between symptom-free and symptomatic patients. Conclusion. Mild COVID-19 patients had a wide variety of symptoms and could be symptomatic even one month after the onset of symptoms. The pharmacist-based monitoring system can contribute beneficially to patients through the evaluation of symptoms, reduction of unnecessary visits, and provision of updated information to patients concerning the status of their illness.

中文翻译：

---

COVID-19 门诊患者的临床监测计划：一项前瞻性队列研究

目的。2019 年冠状病毒病 (COVID-19) 与高死亡率和发病率有关。虽然很大一部分 COVID-19 患者症状轻微，但有限数量的临床试验评估了这一大群患者的临床过程。本研究旨在调查非住院 COVID-19 患者的人口统计学和临床​​特征以及合并症。方法。这项前瞻性、观察性队列研究是在 COVID-19 的非住院成年患者（≥18 岁）中进行的。药物治疗服务负责患者评估长达1个月。人口学特征、症状的发作、严重程度、持续时间、实验室数据和住院率通过基于药剂师的监测计划进行评估。结果。在 2020 年 4 月 26 日至 8 月 2 日期间，从转诊到急诊科的 323 名患者中招募了 105 名患者。大多数患者为女性（66.7%），平均年龄为 39.39 岁（SD：±15.82）。症状发作的平均时间为 5.6 天 (SD: ±1.79)。大多数患者出现疲劳（78.1%）、喉咙痛（67.6%）、咳嗽（60%）和肌痛（55.2%）。C反应蛋白、白细胞、淋巴细胞、中性粒细胞与淋巴细胞的比率、血小板与淋巴细胞的比率和血红蛋白水平在前两周显着恢复。）。羟氯喹、萘普生、苯海拉明、阿奇霉素和维生素 D3 是最常见的药物（分别为 98%、96%、94%、68% 和 57%）。40 名患者在 1 个月的随访后没有症状，8 名患者 (7.6%) 需要重新就诊而无需住院。嗅觉丧失（18.1%）和疲劳（17.1%）是最常见的持续症状。无症状患者和有症状患者之间没有显着差异。结论. 轻度 COVID-19 患者有多种症状，甚至可能在症状出现一个月后出现症状。基于药剂师的监测系统可以通过评估症状、减少不必要的就诊以及向患者提供有关其疾病状态的最新信息来有益于患者。